Oct 17, 2023, 16:41
Christine Lovly: Zenocutuzumab (aka Zeno). This is a great Precision Medicine story!
Quoting Christine Lovly, Ingram Associate Professor of Medicine at Vanderbilt University, on X/Twitter:
” Zenocutuzumab (aka Zeno).
- This is a great Precision Medicine story!
- HER2xHER3 bispecific Ab,
- “Dock and Block” MOA,
- Tested in pan-cancer with rare NRG1 fusions.”
For the article click here.
Source: Christine Lovly/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14